TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06246630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy and targeted-therapy guided by organoid drug sensitivity test
Description: this study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment, and the study aims to evaluate the clinical effectiveness of the drug and its consistency with in vitro organoid drug sensitivity.
Study: NCT05872282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZIPPER aortic arch stentgraft system
Description: The ZIPPER aortic arch stentgraft system consists of the arch mainbody stentgraft system, the branch artery stentgraft system and the thoracic extension stentgraft system.
Study: NCT05434975

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block
Description: For single shot-ISBP block, 15 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine, a total of 25 ml of local anesthetic, will be administered to all patients.~For the block procedure, an imaginary horizontal line drawn from the thyroid cartilage to the sternocleidomastoid (SCM) muscle will followed and the lateral of the SCM muscle will be cleaned with povidine iodine. At the C6 level to be blocked, the nerve roots will be detected by ultrasound. 25 ml of local anesthetic will be injected around the plexus roots with a 22 G 80 mm echogenic needle. The distribution of the local anesthetic applied to the area, which expands the tissues and separates the nerve roots from other tissues, will be seen on ultrasound.
Study: NCT05150340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-771
Description: Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-771
Description: Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
Study: NCT05511155

Intervention type: OTHER
Intervention: Oxygen therapy
Description: Oxygen therapy will be given for 15 minutes with a non-rebreathing mask.

Intervention type: OTHER
Intervention: Oxygen therapy
Description: Oxygen therapy will be given for 15 minutes with a non-rebreathing mask.

Intervention type: OTHER
Intervention: Oxygen therapy
Description: Oxygen therapy will be given for 15 minutes with a non-rebreathing mask.

Intervention type: OTHER
Intervention: Oxygen therapy
Description: Oxygen therapy will be given for 15 minutes with a non-rebreathing mask.
Study: NCT05375487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbonated Natural Mineral Water
Description: 750 mL/day of carbonated natural mineral water, with high content of bicarbonate, calcium, and magnesium, in three portions of 250 mL (one portion 30 minutes prior to lunch, one during the afternoon and the last portion minutes before dinner), during 4 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low Mineral Water
Description: 750 mL/day of low mineral water (one third prior to lunch, one third during the afternoon and the last third 30 minutes before dinner), during 4 weeks.
Study: NCT03676439

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Spinal Stimulation
Description: Spinal Magnetic Stimulation (TMS) on Lateral Cord Stimulation (LCS), in the search of the improvement of the tone, motor function and speech, in patients with spastic cerebral Palsy.~Due to its non-invasiveness and possible efficacy, the use of Magnetic Spinal Stimulation is proposed to try to prove its therapeutic usefulness.~This is the phase 2/3 clinical test of the method, in the future, and as its use could be extended, if the results were positive, its indications could be extended to other pathological conditions, giving a greater spectrum of spastic patients, potentially benefited.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Spinal Stimulation
Description: Spinal Magnetic Stimulation (TMS) on Lateral Cord Stimulation (LCS), in the search of the improvement of the tone, motor function and speech, in patients with spastic cerebral Palsy.~Due to its non-invasiveness and possible efficacy, the use of Magnetic Spinal Stimulation is proposed to try to prove its therapeutic usefulness.~This is the phase 2/3 clinical test of the method, in the future, and as its use could be extended, if the results were positive, its indications could be extended to other pathological conditions, giving a greater spectrum of spastic patients, potentially benefited.
Study: NCT04863976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Description: Dynamic movements of the joints controlled by the quadriceps muscle (hip and knee)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive stretching
Description: passive stretching of the quadriceps muscle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-stretching
Description: Self-stretching of the quadriceps muscle
Study: NCT04698161

Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria

Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria

Intervention type: OTHER
Intervention: Questionnaire
Description: Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire

Intervention type: OTHER
Intervention: Questionnaire
Description: Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire

Intervention type: OTHER
Intervention: Medical examination
Description: Blood pressure measurement, abdominal and thoracic physical examination

Intervention type: OTHER
Intervention: Medical examination
Description: Blood pressure measurement, abdominal and thoracic physical examination
Study: NCT06442501

Intervention type: OTHER
Intervention: routine care
Description: routine care

Intervention type: OTHER
Intervention: routine care
Description: routine care
Study: NCT05233878

Intervention type: OTHER
Intervention: Characterization of a population with cervical paragangliomas
Description: Characterization of a population with sporadic or genetically predisposed cervical paragangliomas in order to evaluate : the initial presentation of the PGL, patients management and patients outcome
Study: NCT04333680

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Focused Assessment of Sonography for Trauma Exam
Description: Speed and image quality of ultrasound exams performed with either transducer specified in the arms.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Focused Assessment of Sonography for Trauma Exam
Description: Speed and image quality of ultrasound exams performed with either transducer specified in the arms.
Study: NCT04935307

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI and paraclinical tests
Description: The patients and controls will be evaluated using MRI and furthermore a large test battery of questionnaires and paraclinical tests. Including the following test: MCS checklist, BDS-Checklist, Symptom Checklist-92 (SCL-92), Whiteley-8, SF-36, Major Depression Inventory (MDI), GAD-10 anxiety scale, and related questionnaire, behavioral olfactory test (TDI), habituation test, pain measurement thresholds tests, Heart Rate Variability and cognitive testing.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI and paraclinical tests
Description: The patients and controls will be evaluated using MRI and furthermore a large test battery of questionnaires and paraclinical tests. Including the following test: MCS checklist, BDS-Checklist, Symptom Checklist-92 (SCL-92), Whiteley-8, SF-36, Major Depression Inventory (MDI), GAD-10 anxiety scale, and related questionnaire, behavioral olfactory test (TDI), habituation test, pain measurement thresholds tests, Heart Rate Variability and cognitive testing.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI and paraclinical tests
Description: The patients and controls will be evaluated using MRI and furthermore a large test battery of questionnaires and paraclinical tests. Including the following test: MCS checklist, BDS-Checklist, Symptom Checklist-92 (SCL-92), Whiteley-8, SF-36, Major Depression Inventory (MDI), GAD-10 anxiety scale, and related questionnaire, behavioral olfactory test (TDI), habituation test, pain measurement thresholds tests, Heart Rate Variability and cognitive testing.
Study: NCT04891224

Intervention type: OTHER
Group type: OTHER
Intervention: Pathway Platform mobile app
Description: The pathway platform intervention involves 3 components: 1. The patient facing app which will: a) Gather health information related to depression management and patient-Provider engagement. b) Clinical data collection; PHQ-9, WHO-5, PDQ-D-5, medication adherence and side effects, goal setting and goal tracking. c) Research data; Patient Activation Measure -13\[PAM-13\], CollaboRATE, and Work and Social Adjustment Scale \[WSAS\]. 2. Electronic Medical Record Integration - a) Data collected in the app is accessible to care team in real time. b) Provide a longitudinal summary to assist in decision making and depression management. 3. Educational Scaffolding - a) Training program describing how the Pathway Platform can support care team members in clinical processes related to measurement-based care and shared-decision making. b) Includes ongoing feedback with up to three audit cycles.
Study: NCT05291390

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pyronaridine Tetraphosphate
Description: Via oral capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyronaridine Tetraphosphate
Description: Via oral capsules.
Study: NCT05928442

Intervention type: DEVICE
Intervention: in vitro diagnostic medical device
Description: Collection of 2 saliva samples at inclusion.

Intervention type: DEVICE
Intervention: in vitro diagnostic medical device
Description: Collection of 2 saliva samples at inclusion.

Intervention type: DEVICE
Intervention: in vitro diagnostic medical device
Description: Collection of 2 saliva samples at inclusion.

Intervention type: BEHAVIORAL
Intervention: Completion of a self-questionnaire
Description: Completion of a self-questionnaire on symptom and quality-of-life at inclusion.

Intervention type: BEHAVIORAL
Intervention: Completion of a self-questionnaire
Description: Completion of a self-questionnaire on symptom and quality-of-life at inclusion.

Intervention type: BEHAVIORAL
Intervention: Completion of a self-questionnaire
Description: Completion of a self-questionnaire on symptom and quality-of-life at inclusion.

Intervention type: DEVICE
Intervention: in vitro diagnostic medical device
Description: Collection of 1 saliva sample at the follow-up visit.

Intervention type: DEVICE
Intervention: in vitro diagnostic medical device
Description: Collection of 1 saliva sample at the follow-up visit.
Study: NCT05230251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PNT2002
Description: Men randomized to receive 177Lu-PSMA will receive 1 cycle of 177Lu-PSMA at a dose of 6.8MBq administered intravenously 2 weeks prior to the planned HDR administration in the Department of Nuclear Medicine as per local practice for the administration of therapeutic radiopharmaceuticals and consistent with good practices.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Radiation
Description: HDR brachytherapy will be administered as per local practice. All procedures will be conducted under general anesthesia in a dedicated brachytherapy suite using transrectal three dimensional ultrasound for image guidance. For all HDR fractions at least 10Gy will be delivered to the entire prostate with a boost to 13.5Gy to the involved prostate as determined by biopsy and PSMA PET/MRI results. In instances of multi-focal/diffuse involvement of the prostate, the entire prostate will receive 13.5Gy/fraction.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High Dose Radiation
Description: HDR brachytherapy will be administered as per local practice. All procedures will be conducted under general anesthesia in a dedicated brachytherapy suite using transrectal three dimensional ultrasound for image guidance. For all HDR fractions at least 10Gy will be delivered to the entire prostate with a boost to 13.5Gy to the involved prostate as determined by biopsy and PSMA PET/MRI results. In instances of multi-focal/diffuse involvement of the prostate, the entire prostate will receive 13.5Gy/fraction.
Study: NCT05219136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Fasting Group
Description: a new fasting protocol is applied to subjects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Fasting Group
Description: a conventional fasting protocol is applied to subjects.
Study: NCT05616312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Teach Back
Description: Patients will receive teach-back education while they fill out questionnaires.
Study: NCT06584591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined (Robotic balance training and high-definition transcranial direct current stimulation)
Description: The robotic platform will train the participants to maintain dynamic balance in the sagittal and the transverse planes (mediolateral and anterior-posterior directions) and engage in core stability and trunk control with seated balance exercises. In addition, high-definition transcranial direct current stimulation (HD-tDCS) will be used as an adjuvant to robotic balance training by priming the corticospinal circuits.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Combined (Robotic balance training and high-definition transcranial direct current stimulation)
Description: The robotic platform will train the participants to maintain dynamic balance in the sagittal and the transverse planes (mediolateral and anterior-posterior directions) and engage in core stability and trunk control with seated balance exercises. In addition, high-definition transcranial direct current stimulation (HD-tDCS) will be used as an adjuvant to robotic balance training by priming the corticospinal circuits.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Balance Training
Description: Participants in this group will receive a standard-of-care balance training administered by the Physical therapist.
Study: NCT06585735

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Proteolytic enzyme fortified protein supplement
Description: Group I receive Enzotein 15 gms (proteolytic enzyme with 70000 Hb unit tyrosine (HUT) fortified with 15 gms of whey protein), given for 6 weeks. Enzotein will be provided by (Mylin Biotech India Ltd.)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Proteolytic enzyme fortified protein supplement
Description: Group I receive Enzotein 15 gms (proteolytic enzyme with 70000 Hb unit tyrosine (HUT) fortified with 15 gms of whey protein), given for 6 weeks. Enzotein will be provided by (Mylin Biotech India Ltd.)
Study: NCT05699668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT Angiography
Description: 2 views per eye (one centered on the fovea, one centered on the optic nerve), in 6x6 mm, using the OCT-A Plexelite®.~Acquisition time per image: about 10 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT Angiography
Description: 2 views per eye (one centered on the fovea, one centered on the optic nerve), in 6x6 mm, using the OCT-A Plexelite®.~Acquisition time per image: about 10 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT Angiography
Description: 2 views per eye (one centered on the fovea, one centered on the optic nerve), in 6x6 mm, using the OCT-A Plexelite®.~Acquisition time per image: about 10 seconds.
Study: NCT05525182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES16001 40 mg
Description: Composition: Elaeocarpus extract 40mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES16001 80 mg
Description: Elaeocarpus extract 80 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES16001 160 mg
Description: Elaeocarpus extract 160 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Tablet: Tablets for oral use indistinguishable from ES16001 in size, appearance, taste and smell

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Tablet: Tablets for oral use indistinguishable from ES16001 in size, appearance, taste and smell
Study: NCT04874506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBM-02
Description: Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBM-02
Description: Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBM-02
Description: Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBM-02
Description: Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
Study: NCT06539026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluid therapy, 300 ml of crystalloid Ringer's solution.
Description: 300 ml by dripping within 30 minutes, the fluid will be repeated by half the amount if needed to reach equal or less than 50% collapsibility.~the fluid that will be used is sterile Ringer's solution which is an isotonic intravenous solution with pH 5.0 - 7.5 and an osmolality of 308mOsmol/kg.
Study: NCT05855863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo Ketone Ester Tablets
Description: Ginkgo Ketone Ester Tablets taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic treatment for six months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic treatment for six months
Study: NCT05498948

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic mixture
Description: orally take .

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Description: orally take .
Study: NCT06585358

Intervention type: OTHER
Intervention: MIPD
Description: This is a non-inverventional study
Study: NCT06171919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organizational Partnerships
Description: Component 1 is a comprehensive training for all MLP care providers delivered to clinical, social and behavioral, and legal staff to establish a collaborative environment. Component 2 consists of the screening tool and screening protocol that is designed to identify health-harming legal needs and risks of formerly incarcerated individuals living with HIV. Component 3 includes the provision of legal support.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV Continuum Care
Description: Participants will be included in the pilot trial. The investigative team will work with the staff at Hope and Help Inc. to identify and recruit those out of care through reviewing electronic medical records.
Study: NCT06515639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet therapy for Classic IF diet group
Description: The 16:8 intermittent fasting model was applied for six weeks. Time restrictions were tailored to fit the participants' lifestyles, with feeding times set between 10:00-12:00 and 18:00-20:00 for all participants. The classic intermittent fasting diet was planned with a macronutrient distribution of 45-60% carbohydrates, 10-15% protein, and 25-30% fat. Additionally, total energy intake was reduced by 500-750 kcal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet therapy for low carb-High fat IF diet group
Description: The 16:8 intermittent fasting model was applied for six weeks. Time restrictions were tailored to fit the participants' lifestyles, with feeding times set between 10:00-12:00 and 18:00-20:00 for all participants.The low carb-high fat intermittent fasting diet included 10-30% carbohydrates and 50-65% fat.Additionally, total energy intake was reduced by 500-750 kcal.
Study: NCT06566001

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: control group
Description: socket shield technique and allogenic bone graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: control group
Description: socket shield technique and allogenic bone graft
Study: NCT04749290

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study Formula
Description: Study infant formula for term infants containing OPO and CPP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Formula
Description: Study infant formula for term infants containing OPO and CPP
Study: NCT05264324

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maximal Exercise Capacity
Description: Maximal Exercise Capacity in incremental ramp exercise tests.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maximal Exercise Capacity
Description: Maximal Exercise Capacity in incremental ramp exercise tests.
Study: NCT06197451

Intervention type: OTHER
Intervention: Turkish Version of M. D. Anderson Dysphagia Inventory
Description: Turkish Validation and Cultural Adaptation of M. D. Anderson Dysphagia Inventory in Neurologic Patients

Intervention type: OTHER
Intervention: Turkish Version of M. D. Anderson Dysphagia Inventory
Description: Turkish Validation and Cultural Adaptation of M. D. Anderson Dysphagia Inventory in Neurologic Patients
Study: NCT06184295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TBI - Intervention Group
Description: The participants will receive 10 customized robotic balance training sessions to improve balance using the Hunova robotic device. Each session will last for up to 1.5 hours. The training may include standing or sitting on the robotic balance platform and performing the following tasks: maintaining balance when the platform becomes unstable or moving in various directions, or in an inclination; these tasks may be performed as instructed with eyes open or eyes closed condition; move in different directions to reach targets with my hands; stand on one leg or heel to toe and maintain balance; perform head or torso rotation while standing or sitting. All training will be performed with an overhead harness and a spotter will be present at all times.